GlassScriptPhysician profile
Joseph T Andrzejewski
NPI 1194169664
$3,917.15
in general payments reported to CMS, 2019-2025
34 companies · $607 in 2025
The $607 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $552 · 2021: $418 · 2022: $669 · 2023: $734 · 2024: $645 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.11 |
| Education | $140.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $654.43 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $426.39 | 2019-2025 | |
| Astellas Pharma US INC | $378.78 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $342.50 | 2021-2025 | |
| Exact Sciences Corporation | $286.52 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $147.92 | 2020-2024 | Aptima |
| Exeltis, USA INC. | $142.12 | 2020-2023 | Slynd |
| Lupin INC. | $114.14 | 2019-2020 | |
| Gilead Sciences, INC. | $105.77 | 2022-2023 | |
| Dexcom, INC. | $99.68 | 2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $88.83 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $87.66 | 2021-2024 | |
| Scynexis, INC. | $82.88 | 2022 | |
| Abbvie INC. | $80.74 | 2019-2020 | |
| Millicent US INC | $78.60 | 2019-2024 | Femring, Intrarosa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $78.59 | 2021-2025 | |
| Therapeuticsmd, INC. | $78.25 | 2021-2022 | |
| Smith+Nephew, INC. | $65.94 | 2019-2023 | Pico |
| Sumitomo Pharma America, INC. | $63.90 | 2024-2025 | Myfembree |
| Mylan Pharmaceuticals INC. | $57.67 | 2021-2022 | |
| Daiichi Sankyo INC. | $53.07 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $51.96 | 2019-2020 | |
| Agile Therapeutics, INC. | $49.16 | 2021-2022 | |
| Radius Health, INC. | $46.84 | 2019-2024 | Tymlos |
| Insulet Corporation | $44.68 | 2024-2025 | Omnipod |
| Convatec INC. | $38.88 | 2023 | |
| Shield Therapeutics INC | $36.17 | 2023-2024 | Accrufer |
| Bsn Medical INC | $27.53 | 2022 | |
| Organon LLC | $26.65 | 2025 | Jada System |
| Coopersurgical, INC. | $19.92 | 2025 | Ally II Ups |
| Avion Pharmaceuticals | $16.65 | 2020 | |
| Avanos Medical | $16.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.63 | 2025 | Camzyos |
| Roche Diagnostics Corporation | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Andrzejewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.